Literature DB >> 28229118

Petechial, purpuric, and ecchymotic presentation of cutaneous Cryptococcus in mantle cell lymphoma.

Christie D Kimball1, Allison Cruse2, Lauren Craig2, Joy King3, Stephen Helms2, Julie Wyatt2, Jeremy Jackson2, Robert Brodell2.   

Abstract

Entities:  

Keywords:  Cryptococcus; HIV-negative; MCL, mantle cell lymphoma; chemotherapy; cutaneous Cryptococcus; mantle cell lymphoma

Year:  2017        PMID: 28229118      PMCID: PMC5311429          DOI: 10.1016/j.jdcr.2016.12.001

Source DB:  PubMed          Journal:  JAAD Case Rep        ISSN: 2352-5126


× No keyword cloud information.

Introduction

Cryptococcus neoformans is an encapsulated, ubiquitous fungus that can infect the skin. Cutaneous Cryptococcus usually occurs after dissemination of a respiratory infection but can result from direct contact to the skin.1, 2, 3 Although classically seen in HIV-infected patients, cryptococcal infections also occur in HIV-negative individuals with or without other immune deficiencies. A case of cutaneous Cryptococcus in an HIV-negative patient with mantle cell lymphoma (MCL) is presented to highlight unusual morphologic features that were found.

Case report

A 71-year-old, HIV-negative white man with MCL was admitted to the hospital with malaise, fatigue, shortness of breath, abdominal pain, hepatosplenomegaly, constipation, and night sweats. After the initial diagnosis of MCL 7 months previously, he received 3 doses of bendamustine-rituximab, each 1 month apart. The MCL did not respond to rituximab, and the patient was started on ibrutinib (560 mg/d) 4 months before admission, which also failed to stall disease progression, prompting another switch of chemotherapeutic agent. Bortezomib infusions on days 1, 4, 8, and 11 were begun 1 month before admission. On the day of admission, the patient came to the hospital to begin his second cycle of bortezomib complaining of a rash of 2 weeks' duration. He was admitted, and all chemotherapy was held. He was normotensive and afebrile with oxygen saturation of 97%. Physical examination found a slowly expanding, asymptomatic, rash with 10- 30-cm patches of dusky erythema studded with 1- to 2-mm purpuric papules that appeared bilaterally on the forearms, antecubital fossae, right side of the neck, right inguinal fold, and lower abdomen. In addition, scattered pin-point petechial and larger ecchymotic macules were present on the upper extremities and trunk (Fig 1). A punch biopsy specimen was obtained from purpuric papules with an erythematous base. One-half was sent for pathologic examination and one-half for bacterial (routine and anaerobes), acid-fast bacilli, and fungal cultures. Encapsulated yeast was identified on hematoxylin-eosin–stained sections (Fig 2). Gomori methenamine silver (Fig 3) and periodic acid–Schiff stained the walls of the yeast. Mucicarmine stained the thick capsules of these organisms. Blood and tissue cultures both grew Cryptococcus. The patient was started on fluconazole, which was escalated to amphotericin B and flucytosine. Despite multiple platelet transfusions, the patient had persistent thrombocytopenia, and he died 2 weeks after admission.
Fig 1

Secondary cutaneous Cryptococcus. Patch of dusky erythema on the right abdomen with central ecchymosis containing numerous slightly raised 1- to 2-mm purpuric papules.

Fig 2

Cryptococcus. Numerous round or ovoid yeast cells with thin dark walls and thick clear capsules are present in the dermis. Occasional narrow based budding is noted. (Hematoxylin-eosin stain; original magnifications: A, × 400; B, × 100.)

Fig 3

Cryptococcus. The thin walls of the yeast cells are stained black (Gomori methenamine silver stain; original magnification: × 400.)

Discussion

Primary cryptococcal infections of the skin are rare and are not usually associated with underlying immune compromise; solitary lesions on uncovered areas such as the hands have occurred in individuals performing outdoor activities in rural areas with exposure to bird droppings. Cutaneous Cryptococcus is most commonly a secondary infection after dissemination of a primary respiratory infection in an immunocompromised individual. This patient's immune system was likely compromised by his aggressive lymphoma and chemotherapy treatment. Even when properly treated as in this case, MCL generally carries a poor prognosis. Cryptococcosis can present with a myriad of cutaneous manifestations. Most commonly, molluscoid, umbilicated or ulcerated papules, nodules, or plaques present with or without background erythema.1, 4, 6, 7 Presentation with asymptomatic petechial, purpural, or ecchymotic rash is rare although previously described in another thrombocytopenic lymphoma patient. It was postulated that red blood cell extravasation occurred as a result of direct vascular injury by disseminated Cryptococcus. Compromise of blood vessel walls in combination with thrombocytopenia leads to hemorrhage. Despite a broad differential diagnosis for petechiae and purpura in the setting of lymphoma, this case underscores the importance of considering an atypical presentation of a deep fungal infection. Early skin biopsy for histopathology and fungal culture is essential in patients in whom disseminated Cryptococcus is suspected, as dermatologic findings can be the presenting sign of this opportunistic infection. Blood cultures should also be performed to identify cryptococcemia. Immediate management of disseminated cryptococcosis may include fluconazole monotherapy (100–400 mg/d) or amphotericin B (0.3–1 mg/kg/d) with or without synergistic flucytosine (75–150 mg/kg/d). Amphotericin B plus flucytosine is the most effective therapy and is preferred in immunosuppressed patients. Unfortunately, therapy often proves to be ineffective in halting the disease progression if administered too late in the disease course.4, 7
  7 in total

1.  Disseminated cryptococcosis with cutaneous lesions.

Authors:  W Z Mostafa; E A Ishak; E M Ekladious; H H Arnaout
Journal:  J Dermatol       Date:  1996-03       Impact factor: 4.005

Review 2.  Mantle cell lymphoma.

Authors:  Stefano A Pileri; Brunangelo Falini
Journal:  Haematologica       Date:  2009-11       Impact factor: 9.941

3.  Cutaneous involvement with Cryptococcus neoformans in AIDS.

Authors:  G Ghigliotti; R De Marchi
Journal:  J Am Acad Dermatol       Date:  1995-05       Impact factor: 11.527

4.  Cryptococcosis in human immunodeficiency virus-negative patients.

Authors:  Sasisopin Kiertiburanakul; Sirirat Wirojtananugoon; Roongnapa Pracharktam; Somnuek Sungkanuparph
Journal:  Int J Infect Dis       Date:  2005-11-09       Impact factor: 3.623

5.  Disseminated cryptococcosis presenting as palpable purpura.

Authors:  M H Greene; A M Macher; A D Hernandez; K J Tomecki; B Chabner
Journal:  Arch Intern Med       Date:  1978-09

6.  Cutaneous manifestations of disseminated cryptococcosis.

Authors:  L Dimino-Emme; A W Gurevitch
Journal:  J Am Acad Dermatol       Date:  1995-05       Impact factor: 11.527

Review 7.  Secondary cutaneous cryptococcosis: case report and review of 22 cases.

Authors:  L Barfield; D Iacobelli; K Hashimoto
Journal:  J Cutan Pathol       Date:  1988-12       Impact factor: 1.587

  7 in total
  1 in total

Review 1.  Cryptococcus neoformans empyema in a patient receiving ibrutinib for diffuse large B-cell lymphoma and a review of the literature.

Authors:  Christopher David Swan; Thomas Gottlieb
Journal:  BMJ Case Rep       Date:  2018-07-18
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.